Analyst Price Targets — EOLS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 4, 2026 12:32 pm | Uy Ear | Mizuho Securities | $15.00 | $4.70 | TheFly | Evolus price target lowered to $15 from $19 at Mizuho |
| January 22, 2026 12:15 pm | — | BTIG | $13.00 | $4.90 | TheFly | Evolus price target lowered to $13 from $18 at BTIG |
| January 13, 2026 12:12 pm | Annabel Samimy | Stifel Nicolaus | $17.00 | $5.77 | TheFly | Evolus price target lowered to $17 from $20 at Stifel |
| December 1, 2025 9:34 pm | Vamil Divan | Mizuho Securities | $19.00 | $6.82 | StreetInsider | Evolus (EOLS) PT Lowered to $19 at Mizuho |
| October 3, 2024 6:57 am | Douglas Tsao | H.C. Wainwright | $27.00 | $17.05 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Evolus (EOLS) |
| September 13, 2024 5:26 am | Balaji Prasad | Barclays | $20.00 | $16.46 | TheFly | Evolus price target raised to $20 from $16 at Barclays |
| September 13, 2024 5:11 am | Vamil Divan | Mizuho Securities | $25.00 | $16.46 | StreetInsider | Evolus (EOLS) PT Raised to $25 at Mizuho |
| January 29, 2024 3:32 am | Balaji Prasad | Barclays | $16.00 | $13.47 | StreetInsider | Barclays Upgrades Evolus (EOLS) to Overweight |
Latest News for EOLS
Evolus (NASDAQ: EOLS) executives told investors at Needham and Company's 25th Annual Healthcare Conference that the company is pursuing double-digit growth and a transition to full-year profitability as it expands beyond its flagship neurotoxin Jeuveau and scales its newer hyaluronic acid (HA) filler line, Evolysse. In a fireside chat moderated by Needham healthcare analyst Serge Belanger,
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2026 financial results on Monday, May 4, 2026, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that…
JPMorgan Chase and Co. decreased its holdings in Evolus, Inc. (NASDAQ: EOLS) by 35.5% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 446,311 shares of the company's stock after selling 246,175 shares during the quarter. JPMorgan Chase and Co. owned about 0.69%
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 14, 2026, at 3:45 PM ET. The fireside…
Evolus, Inc. (NASDAQ: EOLS - Get Free Report) insider Rui Avelar sold 3,119 shares of the firm's stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $4.75, for a total transaction of $14,815.25. Following the transaction, the insider directly owned 427,423 shares in the company, valued
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EOLS.
U.S. House Trading
No House trades found for EOLS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.